Giuseppe Fornarini

Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer

Thomas Powles, Begoña P. Valderrama, Shilpa Gupta et al. · New England Journal of Medicine · 2024 · 764 citations

Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab

Ugo De Giorgi, Giuseppe Procopio, Diana Giannarelli et al. · Clinical Cancer Research · 2019 · 233 citations · Full text

Randomized Trial of Intravenous Iron Supplementation in Patients With Chemotherapy-Related Anemia Without Iron Deficiency Treated With Darbepoetin Alfa

Paolo Pedrazzoli, A. Farris, Salvatore Del Prete et al. · Journal of Clinical Oncology · 2008 · 167 citations · Full text

LBA6 EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC)

Thomas Powles, Begoña P. Valderrama, Shilpa Gupta et al. · Annals of Oncology · 2023 · 131 citations · Full text

Urology, Genitourinary Cancer, Medicine +6

Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised ‘GISCAD’ trial

Roberto Labianca, Alberto F. Sobrero, L. Isa et al. · Annals of Oncology · 2010 · 108 citations · Full text

Surgical Oncology, Gastrointestinal Oncology, Medicine +6